NPC1L1 and cancer: Recently, Kobberø Lauridsen et al. reveal that the long-term genetic inhibition of NPC1L1 (encoding the target of ezetimibe) did not increase the cancer risk of 67,257 patients, and showed that the prolonged treatment with ezetimibe is less likely to increase the risk of cancer (Kobberø Lauridsen et al., 2017).